HALOZYME THERAPEUTICS INC

Halozyme insiders show confidence: President David Ramsay buys 10k shares amid a new drug‑delivery platform and capital raise.

Halozyme insider Krishnan Mahesh buys low at $38.46 and sells high at $75 – a bullish sign for the biotech’s upside potential and earnings momentum.

CEO Torley’s modest 20k share purchase reflects a routine, rule‑based plan amid Halozyme’s growing hyaluronidase platform and bullish Q1 growth.

Halozyme insider sale by Connaughton Bernadette: 1,625 shares at $66.21—explained in context of her trading pattern, stock trend, and future outlook.

Halozyme CEO’s $1.4M share purchase signals confidence amid strong earnings and a $1 bn buy‑back program, hinting at upside for investors.

Halozyme insider buying signals confidence amid new GSK and Oruka drug‑delivery deals, hinting at potential upside for investors.

Halozyme insider sales trend: Connaughton Bernadette’s latest 1,625‑share sale hints at cautious leadership amid upcoming CFO hire and earnings. Learn the implications.

CEO Tor Helen’s $12.07 buy of 10,000 Halozyme shares signals insider confidence in the company’s enzyme‑conjugated platform and its new Australian partnership, hinting at potential upside despite market volatility.

CEO Tor Helen’s $12.07 insider buy of 20 000 Halozyme shares signals deep confidence in its hyaluronidase tech—an attractive “buy‑low” move without dilution.

Insider buying by Halozyme’s COO signals confidence in its hyaluronidase pipeline and future growth, despite a recent share price dip.